- Home
- NNOX vs ACIU Comparison
NNOX vs ACIU Comparison
Compare NNOX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNOX
- ACIU
- Stock Information
- Founded
- NNOX 2011
- ACIU 2003
- Country
- NNOX Israel
- ACIU Switzerland
- Employees
- NNOX N/A
- ACIU N/A
- Industry
- NNOX Medical Electronics
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- NNOX Health Care
- ACIU Health Care
- Exchange
- NNOX Nasdaq
- ACIU Nasdaq
- Market Cap
- NNOX 253.8M
- ACIU 213.3M
- IPO Year
- NNOX 2020
- ACIU 2016
- Fundamental
- Price
- NNOX $3.50
- ACIU $2.86
- Analyst Decision
- NNOX Strong Buy
- ACIU Strong Buy
- Analyst Count
- NNOX 2
- ACIU 2
- Target Price
- NNOX $8.50
- ACIU $10.00
- AVG Volume (30 Days)
- NNOX 1.5M
- ACIU 345.6K
- Earning Date
- NNOX 11-20-2025
- ACIU 11-04-2025
- Dividend Yield
- NNOX N/A
- ACIU N/A
- EPS Growth
- NNOX N/A
- ACIU N/A
- EPS
- NNOX N/A
- ACIU N/A
- Revenue
- NNOX $12,302,000.00
- ACIU $5,482,957.00
- Revenue This Year
- NNOX $20.50
- ACIU N/A
- Revenue Next Year
- NNOX $64.10
- ACIU $1,022.98
- P/E Ratio
- NNOX N/A
- ACIU N/A
- Revenue Growth
- NNOX 15.19
- ACIU N/A
- 52 Week Low
- NNOX $2.78
- ACIU $1.43
- 52 Week High
- NNOX $11.00
- ACIU $4.00
- Technical
- Relative Strength Index (RSI)
- NNOX 51.20
- ACIU 40.94
- Support Level
- NNOX $2.78
- ACIU $3.20
- Resistance Level
- NNOX $3.13
- ACIU $3.23
- Average True Range (ATR)
- NNOX 0.25
- ACIU 0.26
- MACD
- NNOX 0.03
- ACIU -0.07
- Stochastic Oscillator
- NNOX 57.92
- ACIU 1.18
About NNOX NANO-X IMAGING LTD
Nano X Imaging Ltd is engaged in the business of manufacturing medical imaging systems. It offers a Nanox System which is a combination of hardware and software. It develops a prototype of the Nanox.ARC, a medical imaging system incorporating its novel digital X-ray source; and Nanox.CLOUD, a companion cloud-based software that will allow for the delivery of medical screening as a service. It has three business segments: Nanox.ARC division, the radiology services division and the AI solutions division. Key revenue is generated from Radiology Services.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.